JAK V617F Missense Mutation is Absent in Pancreatic Cancer

Overview

Journal Gut

Specialty Gastroenterology

Date 2007 Jul 13

PMID 17625156

Citations 4

Authors

H M Kocher

L Mears

N C Lea

K Raj

G J Mufti

Affiliations

Soon will be listed here.

Citing Articles

TPH1 and 5-HT Receptor Overexpression Leading to Gemcitabine-Resistance Requires Non-Canonical Permissive Action of EZH2 in Pancreatic Ductal Adenocarcinoma.

Chaudhary P, Guragain D, Chang J, Kim J Cancers (Basel). 2021; 13(21).

PMID: 34771469 PMC: 8582390. DOI: 10.3390/cancers13215305.

Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer.

Adamo P, Cowley C, Neal C, Mistry V, Page K, Dennison A Oncotarget. 2017; 8(50):87221-87233.

PMID: 29152076 PMC: 5675628. DOI: 10.18632/oncotarget.20250.

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.

Garrido-Laguna I, Hidalgo M Nat Rev Clin Oncol. 2015; 12(6):319-34.

PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53.

The two faces of Janus kinases and their respective STATs in mammary gland development and cancer.

Wagner K, Schmidt J J Carcinog. 2012; 10:32.

PMID: 22279417 PMC: 3262999. DOI: 10.4103/1477-3163.90677.

References

Scholz A, Heinze S, Detjen K, Peters M, Welzel M, Hauff P . Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology. 2003; 125(3):891-905. DOI: 10.1016/s0016-5085(03)01064-3. View

Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S . Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett. 2003; 201(1):107-16. DOI: 10.1016/s0304-3835(03)00482-8. View

VenkataSubbaRao K, Choudary A, Freeman J . Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res. 2005; 65(7):2861-71. DOI: 10.1158/0008-5472.CAN-04-2396. View

Rahaman S, Vogelbaum M, Haque S . Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res. 2005; 65(7):2956-63. DOI: 10.1158/0008-5472.CAN-04-3592. View

Steensma D, McClure R, Karp J, Tefferi A, Lasho T, Powell H . JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained. Leukemia. 2006; 20(6):971-8. DOI: 10.1038/sj.leu.2404206. View

Scott L, Tong W, Levine R, Scott M, Beer P, Stratton M . JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356(5):459-68. PMC: 2873834. DOI: 10.1056/NEJMoa065202. View

Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y . Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006; 131(1):179-93. DOI: 10.1053/j.gastro.2006.04.025. View

Han Y, Amin H, Franko B, Frantz C, Shi X, Lai R . Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood. 2006; 108(8):2796-803. DOI: 10.1182/blood-2006-04-017434. View

Huang C, Cao J, Huang K, Zhang F, Jiang T, Zhu L . Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci. 2006; 97(12):1417-23. PMC: 11159136. DOI: 10.1111/j.1349-7006.2006.00340.x. View

10.

Campbell P, Green A . The myeloproliferative disorders. N Engl J Med. 2006; 355(23):2452-66. DOI: 10.1056/NEJMra063728. View

11.

Patel R, Lea N, Heneghan M, Westwood N, Milojkovic D, Thanigaikumar M . Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006; 130(7):2031-8. DOI: 10.1053/j.gastro.2006.04.008. View